Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...
June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...
CHICAGO -- The STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with investigator-selected tyrosine kinase inhibitors (TKIs) for patients with newly diagnosed ...
NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel may be superior to the already highly effective standard medicine Gleevec in treating newly diagnosed patients with chronic ...
SurvivorNet on MSN
From chemotherapy to targeted pills: A new era in chronic myeloid leukemia and what asciminib could mean for patients
From Chemotherapy to Targeted Pills: A New Era in Chronic Myeloid Leukemia and What Asciminib Could Mean for Patients ...
The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...
The FDA has cleared Inhibikase Therapeutics Inc.'s IND application for IkT-001Pro for the treatment of chronic myelogenous leukemia (CML). IkT-001Pro is a prodrug formulation of imatinib mesylate and ...
The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto ...
The chronic phase is the first and most treatable phase of chronic myeloid leukemia. It is characterized by a low percentage of abnormal cells in the blood and bone marrow. With treatment, most people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results